Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Financing Activities (2016 - 2025)

Dexcom (DXCM) has disclosed Cash from Financing Activities for 16 consecutive years, with -$1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 95037.5% to -$1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.7 billion, a 129.5% decrease, with the full-year FY2025 number at -$1.7 billion, down 129.5% from a year prior.
  • Cash from Financing Activities was -$1.5 billion for Q4 2025 at Dexcom, down from -$175.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $939.5 million in Q2 2023 to a low of -$1.5 billion in Q4 2025.
  • A 5-year average of -$164.1 million and a median of -$1.2 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 21948.84% in 2023, then tumbled 95037.5% in 2025.
  • Dexcom's Cash from Financing Activities stood at -$800000.0 in 2021, then dropped by 25.0% to -$1.0 million in 2022, then crashed by 63090.0% to -$631.9 million in 2023, then skyrocketed by 99.75% to -$1.6 million in 2024, then crashed by 95037.5% to -$1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Cash from Financing Activities are -$1.5 billion (Q4 2025), -$175.0 million (Q3 2025), and -$1.7 million (Q2 2025).